Involved fusion genes were NTRK1, RET, FGFR3, FGFR2, BRAF, RAF1, ALK, ROS1, and CLDN18. We suggest that detection of fusion genes by RNA panel sequencing can be beneficial in refractory patients with gastrointestinal or rare cancers, particularly in those with CRC and BTC. This evidence concerns the gene ROS1 and colorectal carcinoma.